HDAC inhibitors (HDACis) are compounds that inhibit the activity of HDACs, leading to hyperacetylation of histones and the reactivation of silenced genes. HDACis have emerged as potential therapeutic agents in cancer treatment. Some well-known HDACis include vorinostat, romidepsin, and panobinostat, which have been approved for the treatment of certain cancers, such as cutaneous T-cell lymphoma and multiple myeloma.
